Yahoo · Sep 9, 2026
Morgan Stanley Just Upped Its Price Target on 'Top Pick' Dell Stock
Evercore raises its price target on Dell stock. Here’s why analyst Amit Daryanani favors owning DELL shares.
NYSE · EVR
Financial Services · Financial - Capital Markets
$270.82
Up+$0.03 (+0.01%)
Updated Sep 16, 2026, 1:51 PM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EVR closed at $270.82 after 20 trading sessions, down 9.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $274.14 | $275.67 | $268.715 | $270.82 | 441.31K |
| Sep 14, 2026 | $277.47 | $280.86 | $272.15 | $275.49 | 391.74K |
| Sep 11, 2026 | $287.87 | $288.235 | $281.04 | $281.21 | 274.74K |
| Sep 10, 2026 | $285.82 | $290.14 | $282.01 | $283.62 | 378.49K |
| Sep 9, 2026 | $293.43 | $296.56 | $287.19 | $287.92 | 299.14K |
| Sep 8, 2026 | $296.63 | $299.40 | $293.80 | $295.67 | 405.34K |
| Sep 4, 2026 | $294.01 | $298.41 | $291.81 | $297.92 | 332.42K |
| Sep 3, 2026 | $292.98 | $300.24 | $292.21 | $296.91 | 416.05K |
| Sep 2, 2026 | $286.15 | $294.65 | $284.54 | $288.69 | 551.81K |
| Sep 1, 2026 | $281.53 | $294.08 | $280.02 | $286.23 | 571.97K |
| Aug 31, 2026 | $287.77 | $289.985 | $284.86 | $286.43 | 607.2K |
| Aug 28, 2026 | $291.40 | $294.55 | $286.79 | $290.11 | 356.77K |
| Aug 27, 2026 | $291.545 | $295.37 | $287.62 | $292.12 | 405.76K |
| Aug 26, 2026 | $289.01 | $294.04 | $286.19 | $291.42 | 493.85K |
| Aug 25, 2026 | $291.61 | $292.341 | $286.6401 | $289.54 | 430.98K |
| Aug 24, 2026 | $292.00 | $294.18 | $287.85 | $290.11 | 499.6K |
| Aug 21, 2026 | $290.37 | $294.61 | $289.5075 | $291.89 | 483.26K |
| Aug 20, 2026 | $302.29 | $302.29 | $286.77 | $287.09 | 519.75K |
| Aug 19, 2026 | $301.04 | $305.93 | $297.62 | $298.38 | 473.38K |
| Aug 18, 2026 | $301.27 | $303.18 | $297.51 | $298.66 | 483.35K |
The latest Smart Investors Daily articles mentioning EVR.
EVR research
Company profile and research snapshot.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | BMO Capital | Market Perform | — |
| Jul 30, 2026 | Keefe, Bruyette & Woods | Outperform | — |
| Jul 30, 2026 | UBS | Neutral | — |
| Jul 30, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 10, 2026 | Keefe, Bruyette & Woods | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Evercore raises its price target on Dell stock. Here’s why analyst Amit Daryanani favors owning DELL shares.
Yahoo · Sep 9, 2026
RJF rallies 17.2% in three months, backed by PCG growth, acquisitions and IB recovery, though rising expenses and brokerage volatility pose risks.
Yahoo · Sep 6, 2026
Evercore said third-quarter capital markets indicators are tracking below expectations, with the firm anticipating investment banking and trading guidance from banks to come in below consensus estimates. In its August 2026 Capital Markets Monthly report, Evercore said investment banking volumes declined 6% year over year in July as lower debt capital markets activity offset increases in equity capital markets and mergers and acquisitions.
Yahoo · Sep 2, 2026
Evercore recently announced that John Pissanos has joined the firm as a senior managing director in its healthcare investment banking group, based in London and focusing on life science tools, diagnostics, and medtech. His move from J.P. Morgan, where he led EMEA life science tools and diagnostics, adds specialized sector expertise that could deepen Evercore’s healthcare advisory capabilities in Europe. We’ll now examine how adding a senior EMEA healthcare banker like John Pissanos may...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning EVR.